Based on 9 Wall Street analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €266.44 with a high forecast of €360.00 and a low forecast of €200.00. The average price target represents a 48.87% change from the last price of €178.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"185":"€185","229":"€229","273":"€273","317":"€317","361":"€361"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":360,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€360.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":266.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€266.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[185,229,273,317,361],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.65,199.98461538461538,213.31923076923078,226.65384615384616,239.98846153846154,253.32307692307694,266.6576923076923,279.9923076923077,293.3269230769231,306.6615384615385,319.99615384615385,333.3307692307692,346.6653846153846,{"y":360,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.65,192.7876923076923,198.92538461538462,205.06307692307692,211.20076923076923,217.33846153846153,223.47615384615386,229.61384615384617,235.75153846153847,241.88923076923078,248.02692307692308,254.1646153846154,260.3023076923077,{"y":266.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.65,187.6769230769231,188.70384615384617,189.73076923076923,190.7576923076923,191.7846153846154,192.81153846153848,193.83846153846153,194.8653846153846,195.8923076923077,196.91923076923078,197.94615384615383,198.97307692307692,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":275.79,"date":1686873600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.18,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.75,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.1,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.08,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.7,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.22,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.55,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.07,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.53,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211.04,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.65,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€360.00

Average Price Target€266.44

Lowest Price Target€200.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

05/28/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

05/22/24

xxxxxxxxxxxxxxxxxx

Goldman Sachs

xxxxxxxxxxxxx

Reiterated

05/17/24

xxxxxxxxxxxxxxxxxx

Kepler Capital

xxxxxxxxxxxxx

Reiterated

05/16/24

xxxxxxxxxxxxxxxxxx

Berenberg Bank

xxxxxxxxxxxxx

Reiterated

04/25/24

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

04/23/24

xxxxxxxxxxxxxxxxxx

UBS

xxxxxxxxxxxxx

Reiterated

04/22/24

xxxxxxxxxxxxxxxxxx

HSBC

xxxxxxxxxxxxx

Reiterated

04/19/24

xxxxxxxxxxxxxxxxxx

Bernstein

xxxxxxxxxxxxx

Reiterated

03/21/24

Dominic Lunn

Credit Suisse

€280.00

Hold

56.45%

Upside

Reiterated

08/11/23

Best Analysts Covering Sartorius Stedim Biotech

Which Analyst Should I Follow If I Want to Buy GB:0RG8 and Sell After:

1 Month

Richard VosserJ.P. Morgan

Success Rate

8/13 ratings generated profit

Average Return

+6.78%

reiterated a buy rating 27 days ago

Copying Richard Vosser's trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +6.78% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Richard VosserJ.P. Morgan

Success Rate

7/13 ratings generated profit

Average Return

+3.52%

reiterated a buy rating 27 days ago

Copying Richard Vosser's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +3.52% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Richard VosserJ.P. Morgan

Success Rate

2/13 ratings generated profit

Average Return

-13.15%

reiterated a buy rating 27 days ago

Copying Richard Vosser's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -13.15% per trade.

2 Years

Odysseas ManesiotisBerenberg Bank

Success Rate

1/7 ratings generated profit

Average Return

-24.21%

reiterated a buy rating 2 months ago

Copying Odysseas Manesiotis's trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -24.21% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0RG8 Analyst Recommendation Trends

Rating

Jan 24

Feb 24

Mar 24

Apr 24

May 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0RG8 has received 11 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 0RG8 average Analyst price target in the past 3 months is €266.44.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0RG8 Financial Forecast

0RG8 Earnings Forecast

Next quarter’s earnings estimate for 0RG8 is €1.06 with a range of €1.06 to €1.06. The previous quarter’s EPS was €0.86. 0RG8 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.78% of the time in the same period. In the last calendar year 0RG8 has Underperformed its overall industry.

0RG8 Sales Forecast

Next quarter’s sales forecast for 0RG8 is €706.12M with a range of €706.12M to €706.12M. The previous quarter’s sales results were €676.30M. 0RG8 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.05% of the time in the same period. In the last calendar year 0RG8 has Underperformed its overall industry.

0RG8 Stock Forecast FAQ

What is GB:0RG8’s average 12-month price target, according to analysts?

Based on analyst ratings, Sartorius Stedim Biotech’s 12-month average price target is €266.44.

What is GB:0RG8’s upside potential, based on the analysts’ average price target?

Sartorius Stedim Biotech has 48.87% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sartorius Stedim Biotech a Buy, Sell or Hold?

Sartorius Stedim Biotech has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 3 hold ratings and 0 sell ratings.

What is Sartorius Stedim Biotech’s share price target?

The average share price target for Sartorius Stedim Biotech is €266.44. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €360.00 ,and the lowest forecast is €200.00. The average share price target represents 48.87% Increase from the current price of €178.972.

What do analysts say about Sartorius Stedim Biotech?

Sartorius Stedim Biotech’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Sartorius Stedim Biotech?

To buy shares of GB:0RG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sartorius Stedim Biotech (0RG8) Share Forecast & Price Target

0RG8 Analyst Ratings

0RG8 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sartorius Stedim Biotech

0RG8 Analyst Recommendation Trends

0RG8 Financial Forecast

0RG8 Earnings Forecast

0RG8 Sales Forecast

0RG8 Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts